Why and when do patients with heart failure and normal left ventricular ejection fraction die? Analysis of >600 deaths in a community long-term study

Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction

Bertram Pitt, Willem J. Remme, Faı̈ez Zannad et al. · New England Journal of Medicine · 2003 · 4.9K citations · Full text

Medicine, Cardiology, Pharmacology +17

The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial

The Lancet · 1999 · 4.9K citations

Medicine, Cardiology, Pharmacology +10

Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction

Theophilus Owan, David O. Hodge, Regina M. Herges et al. · New England Journal of Medicine · 2006 · 4.2K citations

Medicine, Cardiology, Internal Medicine +14

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

Salim Yusuf, Marc A. Pfeffer, Karl Swedberg et al. · The Lancet · 2003 · 3K citations

Medicine, Cardiology, Internal Medicine +12

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

John J.V. McMurray, Jan Östergren, Karl Swedberg et al. · The Lancet · 2003 · 2.6K citations

Medicine, Cardiology, Pharmacology +15